Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q2 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.